zintellect
climb higher

Opportunity Title: FDA Fellowship in Immune Responses to Influenza COVID and Respiratory Syncytia Virus and Adjuvanted Vaccines
Opportunity Reference Code: FDA-CBER-2024-0026

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CBER-2024-0026

How to Apply ***Connect with ORISE...on the GO!*** Download the new ORISE GO mobile app in the Apple App Store or Google Play Store to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts – Click here for detailed information about acceptable transcripts
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity in your email.

Application Deadline 8/31/2024 3:00:00 PM Eastern Time Zone

Description ***Applications will be reviewed on a rolling-basis.**

FDA Office and Location: A research opportunity is currently available in the Office of Vaccines Research and Review (OVRR) at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.

The Center for Biologics Evaluation and Research (CBER) is one Center within the Food and Drug Administration, an Agency within the United States Government's Department of Health and Human Services. CBER's mission is to protect and enhance the public health through the regulation of biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies.

Research Project: A research training opportunity is available for studying of humoral immune responses following SARS CoV-2 (COVID-19), RSV or influenza infections and vaccination in humans as well as animal studies to evaluate antibody responses to infection (influenza, RSV) after vaccination.

Learning Objectives: The candidate will be trained in advanced techniques developed in the lab including in vitro cell cultures (viral infections); virus neutralization assays, cytokine production; whole genome gene-fragment phage display libraries (GFPDL); Surface plasmon resonance (SPR); recombinant protein expression in bacterial and mammalian systems; small animal models (vaccination and infection). Program includes training on mode of action of novel adjuvants used to enhance immune responses to multiple vaccines.

Anticipated Appointment Start Date: 2024. Start date is flexible and will depend on a variety of factors.

Appointment Length: The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation: The appointment is full time.

zintellect
climb higher

Opportunity Title: FDA Fellowship in Immune Responses to Influenza COVID and Respiratory Syncytia Virus and Adjuvanted Vaccines
Opportunity Reference Code: FDA-CBER-2024-0026

Citizenship Requirements: This opportunity is available to U.S. citizens and Lawful Permanent Residents (LPR) only.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA Ethics Requirements

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications

The qualified candidate should have received a bachelor's, master's, or doctoral degree in one of the relevant fields. Degree must have been received within the past three years.

Preferred skills

- Experience in Scientific work in a laboratory set up.

Eligibility Requirements

- **Citizenship:** LPR or U.S. Citizen
- **Degree:** Bachelor's Degree, Master's Degree, or Doctoral Degree received within the last 36 month(s).
- **Discipline(s):**
  - **Life Health and Medical Sciences** (51 👁)
  - **Science & Engineering-related** (1 👁)

Affirmation

I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)

Opportunity Title: FDA Fellowship in Immune Responses to Influenza COVID and Respiratory Syncytia Virus and Adjuvanted Vaccines
Opportunity Reference Code: FDA-CBER-2024-0026

and
I have read the FDA Ethics Requirements.